索引超出了数组界限。 文章摘要
|本期目录/Table of Contents|

[1]曾振宇,白元,赵仙先.Entresto治疗慢性心力衰竭的进展[J].国际心血管病杂志,2017,03:129-131.
点击复制

Entresto治疗慢性心力衰竭的进展(PDF)

《国际心血管病杂志》[ISSN:1006-6977/CN:61-1281/TN]

期数:
2017年03期
页码:
129-131
栏目:
综述
出版日期:
2017-05-30

文章信息/Info

Title:
-
作者:
曾振宇; 白元; 赵仙先
200433 上海,第二军医大学附属长海医院心内科
Author(s):
-
关键词:
脑啡肽酶抑制剂;  心力衰竭;  临床实验;  安全性
Keywords:
-
分类号:
-
DOI:
10.3969/j.issn.1673-6583.2017.03.001
文献标识码:
-
摘要:
该文介绍Entresto治疗心力衰竭的作用机制、临床实验研究、安全性及临床应用等方面的进展,以期为相关工作者提供参考,提高心力衰竭的临床治疗效果。
Abstract:
-

参考文献/References

[1] Roger VL, Weston SA, Redfield MM, et.al. Trends in heart failure incidence and survival in a community-based population[J]. JAMA, 2004, 292(3):344-350.
[2] Levy D, Kenchaiah S, Larson MG, et al. Long-term trends in the incidence of and survival with heart failure[J]. N Engl J Med, 2002, 347(18):1397-1402.
[3] Yancy CW, Jessup M, Bozkurt B, et.al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines[J]. Girculation, 2013, 128(16):1810-1852.
[4] McMurray JJ, Adamopoulos S, Anker SD, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the european society of cardiology. Developed in collaboration with the Heart Failure Association(HFA)of the ESC[J]. Eur J Heart Fail, 2012, 14(8):803-869.
[5] Reed BN, Street SE, Jensen BC. Time and technology will tell: the pathophysiologic basis of neurohormonal modulation in heart failure[J]. Heart Fail Clin, 2014, 10(4):543-557.
[6] von Lueder TG, Sangaralingham SJ, Wang BH, et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure[J]. Circ Heart Fail, 2013, 6(3):594-605.
[7] Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor(ARNi)[J]. J Clin Pharmacol, 2010, 50(4):401-414.
[8] Solomon SD, Zile M, Pieske B, et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial[J]. Lancet, 2012, 380(9851):1387-1395.
[9] Jhund PS, Claggett BL, Voors AA, et al. Elevation in high-sensitivity troponin T in heart failure and preserved ejection fraction and influence of treatment with the angiotensin receptor neprilysin inhibitor LCZ696[J]. Circ Heart Fail, 2014, 7(6):953-959.
[10] Senni M, McMurray JJ, Wachter R, et al. Initiating sacubitril/valsartan(LCZ696)in heart failure: results of TITRATION, a double-blind, randomized comparison of two uptitration regimens[J]. Eur J Heart Fail, 2016, 18(9):1193-1202.
[11] McMurray JJ, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med, 2014, 371(11):993-1004.
[12] McMurray JJ, Packer M, Desai AS, et al. Baseline characteristics and treatment of patients in prospective comparison of ARNi with ACEI to determine impact on global mortality and morbidity in heart failure trial(PARADIGM-HF)[J]. Eur J Heart Fail, 2014, 16(7):817-825.
[13] von Lueder TG, Wang BH, Kompa AR, et al. Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy[J]. Circ Heart Fail, 2015, 8(1):71-78.
[14] Simpson J, Jhund PS, Silva Cardoso J, et al. Comparing LCZ696 with enalapril according to baseline risk using the MAGGIC and EMPHASIS-HF risk scores: an analysis of mortality and morbidity in PARADIGM-HF[J]. J Am Coll Cardiol, 2015, 66(19):2059-2071.
[15] Jhund PS, Fu M, Bayram E, et al. Efficacy and safety of LCZ696(sacubitril-valsartan)according to age: insights from PARADIGM-HF[J]. Eur Heart J, 2015, 36(38):2576-2584.
[16] Bodey F, Hopper I, Krum H. Neprilysin inhibitors preserve renal function in heart failure[J]. Int J Cardiol, 2015, 179:329-330.
[17] Desai AS, Claggett BL, Packer M, et al. Influence of Sacubitril/Valsartan(LCZ696)on 30-day readmission after heart failure hospitalization[J]. J Am Coll Cardiol, 2016, 68(3):241-248.
[18] Filippatos G, Farmakis D, Parissis J, et al. Drug therapy for patients with systolic heart failure after the PARADIGM-HF trial: in need of a new paradigm of LCZ696 implementation in clinical practice[J]. BMC Med, 2015, 13:35.
[19] McMurray J, Packer M, Desai A, et al. A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure[J]. Eur Heart J, 2015, 36(7):434-439.
[20] Ponikowski P, Voors AA, Anker SD, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology(ESC). Developed with the special contribution of the Heart Failure Association(HFA)of the ESC[J]. Eur J Heart Fail, 2016, 18(8):891-975.
[21] Ruilope LM, Dukat A, B?hm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin Ⅱ receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study[J]. Lancet, 2010, 375(9722):1255-1266.
[22] Hersh LB, Rodgers DW. Neprilysin and amyloid beta peptide degradation[J]. Curr Alzheimer Res, 2008, 5(2):225-231.
[23] Vodovar N, Paquet C, Mebazaa A, et al. Neprilysin, cardiovascular, and Alzheimer’s diseases: the therapeutic split?[J]. Eur Heart J, 2015, 36(15):902-905.
[24] Yancy CW, Jessup M, Bozkurt B, et al. 2016 ACC/AHA/HFSA focused update on new pharmacological therapy for heart failure: an update of the 2013 ACCF/AHA guideline for the management of heart failure: a report of the american college of cardiology/american heart association task force on clinical practice guidelines and the heart failure society of america[J]. J Am Coll Cardiol, 2016, 68(13):1476-1488.
[25] Jhund PS, McMurray JJ. The neprilysin pathway in heart failure: a review and guide on the use of sacubitril/valsartan[J]. Heart, 2016, 102(17):1342-1347.

备注/Memo

备注/Memo:
基金项目:国家自然科学基金(8157020494)
通信作者:赵仙先,Email:13601713431@163.com
更新日期/Last Update: 2017-05-30